Literature DB >> 16046285

A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma.

S Ramanathan1, S Karupiah, N K Nair, P L Olliaro, V Navaratnam, W H Wernsdorfer, S M Mansor.   

Abstract

A new approach using a simple solid-phase extraction technique has been developed for the determination of pyronaridine (PND), an antimalarial drug, in human plasma. After extraction with C18 solid-phase sorbent, PND was analyzed using a reverse phase chromatographic method with fluorescence detection (at lambda(ex)=267 nm and lambda(em)=443 nm). The mean extraction recovery for PND was 95.2%. The coefficient of variation for intra-assay precision, inter-assay precision and accuracy was less than 10%. The quantification limit with fluorescence detection was 0.010 microg/mL plasma. The method described herein has several advantages over other published methods since it is easy to perform and rapid. It also permits reducing both, solvent use and sample preparation time. The method has been used successfully to assay plasma samples from clinical pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046285     DOI: 10.1016/j.jchromb.2005.06.034

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Alexander N Freiberg; Huanying Zhou; Julie Dyall; Michael R Holbrook; Manu Anantpadma; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  Antiviral Res       Date:  2020-07-16       Impact factor: 5.970

2.  Pyronaridine Protects against SARS-CoV-2 Infection in Mouse.

Authors:  Ana C Puhl; Giovanni F Gomes; Samara Damasceno; Andre S Godoy; Gabriela D Noske; Aline M Nakamura; Victor O Gawriljuk; Rafaela S Fernandes; Natalia Monakhova; Olga Riabova; Thomas R Lane; Vadim Makarov; Flavio P Veras; Sabrina S Batah; Alexandre T Fabro; Glaucius Oliva; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Sean Ekins
Journal:  ACS Infect Dis       Date:  2022-05-24       Impact factor: 5.578

3.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

4.  Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding.

Authors:  Daniel Blessborn; Karnrawee Kaewkhao; Lijiang Song; Nicholas J White; Nicholas P J Day; Joel Tarning
Journal:  J Pharm Biomed Anal       Date:  2017-08-26       Impact factor: 3.935

5.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.